News summary

D&D Pharmatech advances obesity candidate with muscle-preserving potential

Source: Longevity Technology • Published: 20 Nov 2026, 10:31

Summarized by Masters of Longevity from Longevity Technology.

Preclinical data showed DD18 cut body fat and increased lean mass in models.

D&D Pharmatech advances obesity candidate with muscle-preserving potential
Key Takeaways
  • D&D Pharmatech presented DD18 preclinical results at ObesityWeek 2026.
  • DD18 reduced body fat while increasing lean body mass in models.
  • Evidence was preclinical and presented at a conference, not peer reviewed.
Read the full article at Longevity Technology ↗

Continue exploring

Recommended MoL Picks

MoL PickThe Next Obesity-Drug Race Is About What Weight You LoseRegeneron’s myostatin and activin A antibodies point to a sharper question for the GLP-1 era: not whether people can lose more weight, but whether medicine can preserve the tissue that makes weight loss healthier.MoL PickReducing Inflammation from Ageing Cells: What a Mouse Study FoundResearchers reduced the inflammatory signals released by cells that had stopped dividing. Older mice also improved on some strength and frailty tests. Whether this approach could help people remains unknown.MoL PickCan Exergaming Improve Balance? What Older Adults Should KnowMotion-controlled games may make balance practice easier to repeat. The evidence supports a structured adjunct—not a fall-proofing shortcut.